Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07621146 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

Study acronym: NET-COMPARE
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Mar 2027 → Jun 2027
See other at-risk trials from British Columbia Cancer Agency

Record History

  1. Start date: Sep 15, 2026 to Nov 30, 2026 Primary completion pushed from Mar 2027 to Jun 2027 · Enrollment increased: 51 → 60 participants · Interventions: 18F-AmBF3-TATE PET/CT (Diagnostic Test), 68Ga-DOTATATE PET/CT (Diagnostic Test) to 18F-AmBF3-TATE PET/CT (Diagnostic Test), 68Ga-DOTATATE PET/CT (Diagnostic Test) · 2 more Show 5 more changesShow less
    • Primary completion pushed from Mar 2027 to Jun 2027
    • Enrollment increased: 51 → 60 participants
    • Interventions: 18F-AmBF3-TATE PET/CT (Diagnostic Test), 68Ga-DOTATATE PET/CT (Diagnostic Test) to 18F-AmBF3-TATE PET/CT (Diagnostic Test), 68Ga-DOTATATE PET/CT (Diagnostic Test)
    • Secondary endpoints: details revised at 3 of 5 entries
    • Eligibility criteria expanded, about 5 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.
Trial Details
NCT Number NCT07621146
Lead Sponsor British Columbia Cancer Agency
Conditions Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma, SSTR-expressing Tumors, Medullary Thyroid Carcinoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov